Replies to post #123 on Dermata Therapeutics Inc (DRMA)

[The Night Stalker]

the run to 3.84 was for good reason ,, want to see volume pick up, up from here its peers did big pops. this will to in coming weeks with this rare tiny market cap

[The Night Stalker]

its starting, can see 2.00 today or by friday

[The Night Stalker]

nailed bottom, want to see volume pick up from here, consider offerings as a way to buy cheap shares

[The Night Stalker]

got loaded today, we see some action next week it goes, been a bumpy sick ride, usually i sell at loss, with big board bio techs, hold for events

[The Night Stalker]

going over my 40 biotech watchlist, the offerings are everyday practice on Nasdaq imo our milestone event will be worth the wait

[The Night Stalker]

- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -

- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -

- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -

SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("De

[The Night Stalker]

- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -

- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -

- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -

SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("De

[The Night Stalker]

we see higher volume days ahead-

[The Night Stalker]

once weekly acne application current market has twice daily cream 10 billion market at 5.2m marketcap

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."